Profile data is unavailable for this security.
About the company
Bristol-Myers Squibb Company is a biopharmaceutical company, which is engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for a range of therapeutic classes, which include oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically-synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, Breyanzi, Camzyos, Sotyktu, Onureg, Inrebic, Augtyro, and others. It also provides radiopharmaceutical therapeutics.
- Revenue in USD (TTM)45.01bn
- Net income in USD8.03bn
- Incorporated1933
- Employees34.10k
- LocationBristol-Myers Squibb CoRoute 206 And Province Line RoadPRINCETON 08543United StatesUSA
- Phone+1 (609) 252-4621
- Fax+1 (302) 655-5049
- Websitehttps://www.bms.com/
Mergers & acquisitions
Acquired company | BMY:NYQ since announced | Transaction value |
---|---|---|
RayzeBio Inc | -1.34% | 4.21bn |
Karuna Therapeutics Inc | 0.64% | 13.57bn |
LianBio-Mavacamten Greater China Rights | -7.88% | 350.00m |
Mirati Therapeutics Inc | -8.95% | 5.12bn |